Axsome Therapeutics, Inc.AXSMNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

zacks.com

Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?

Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.

defenseworld.net

Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 30.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,902 shares of the company's stock after acquiring an additional 15,934 shares during the quarter. Universal Beteiligungs

defenseworld.net

Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM

Cabot Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,560 shares of the company's stock, valued at approximately $675,000. Several other hedge funds and other institutional

defenseworld.net

Ari Maizel Sells 7,500 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. The sale was disclosed in a legal filing with the SEC, which is

defenseworld.net

Nick Pizzie Sells 12,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CFO Nick Pizzie sold 12,000 shares of the company's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total value of $2,255,040.00. Following the completion of the sale, the chief financial officer directly owned 42,588 shares

seekingalpha.com

Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline

Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to execution—specifically, controlling SG&A growth relative to incremental pipeline-driven revenue. Pipeline opportunities in Alzheimer's agitation and narcolepsy could conservatively add $375M+ in annual revenue, but value creation hinges on SG&A discipline.

zacks.com

Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com

Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia

AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.

zacks.com

Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

seekingalpha.com

MoneyShow's Best Investment Ideas For 2026: Part 2

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.

globenewswire.com

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively

zacks.com

HALO or AXSM: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers value investors a better bang for their buck right now?

marketbeat.com

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.

fool.com

2 Healthcare Stocks to Buy for 2026 and Beyond

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.

defenseworld.net

Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM

Stanley Laman Group Ltd. acquired a new position in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 17,501 shares of the company's stock, valued at approximately $2,125,000. Other institutional investors have also modified their holdings of the company. Ameritas

defenseworld.net

Axsome Therapeutics (NASDAQ:AXSM) Director Mark Saad Sells 37,577 Shares

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) Director Mark Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares

AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation

zacks.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance